CN109806328A - It is a kind of for treating the compound prescription snake lotus mixture of diabetes - Google Patents
It is a kind of for treating the compound prescription snake lotus mixture of diabetes Download PDFInfo
- Publication number
- CN109806328A CN109806328A CN201910130305.7A CN201910130305A CN109806328A CN 109806328 A CN109806328 A CN 109806328A CN 201910130305 A CN201910130305 A CN 201910130305A CN 109806328 A CN109806328 A CN 109806328A
- Authority
- CN
- China
- Prior art keywords
- parts
- patient
- diabetes
- lotus
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of for treating the compound prescription snake lotus mixture of diabetes, it includes following parts by weight of component: 9 parts of kuh-seng, 12-25 parts of white taste lotus, 30 parts of potentilla discolor, 30-120 parts of Radix Astragali, 20-60 parts of pueraria lobata, 20-50 parts of Chinese yam, 20 parts of Morinda officinalis, 30-50 parts of Radix Salviae Miltiorrhizae, 15 parts of hairyvein agrimony, 10 parts of barberry, l0 parts of fried atractylodes, l0 parts of Yun Ling, l0 parts of radix scrophulariae, l0 parts of stir-baked FRUCTUS CRATAEGI；The present invention has apparent therapeutic effect for type 2 diabetic patient, and the blood glucose level of patient can be effectively reduced, and reduces saccharification hemoglobin content, is slightly better than western medicine to the reduction effect of blood glucose and saccharification hemoglobin content；In addition, the present invention has apparent advantage compared with Western medicine in terms of controlling patient symptom, especially in terms of controlling the symptoms such as more drinks and frequent micturition, the present invention works comparatively fast, can control the symptom of patient in a short time, effect is obvious.
Description
Technical field
The present invention relates to drug fields, and in particular to a kind of for treating the compound prescription snake lotus mixture of diabetes.
Background technique
Diabetes are one kind endocrine system diseases due to caused by the absolutely fiery relative deficiency of insulin secretion, due to human body
Cell reduces the uptake and utilization of carbohydrate, and the blood glucose of patient's body is in higher level.Diabetes do not only result in internal cell
With tissue sugar, fat and protein metabolism disturbance, long-term height sugar stimulation can also cause severe complication and involve kidney, the heart
The main organs such as the cerebrovascular.Modern medicine thinks that the pathogenic factor of 2 patients with type Ⅰ DM includes heredity, environment change, endocrine system
And immune system dysfunction etc., main treatment method include reducing the intake of carbohydrate in diet, promoting pancreas islet
The secretion of element improves peripheral tissues to the sensibility of insulin and inhibition carbohydrate absorption etc..Although Western medicine can be in the short time
The interior blood glucose level for reducing patient reduces the generation of complication, but application may cause patient under drug susceptibility for a long time
Drop, it is necessary to the problems such as escalated dose.Meanwhile for the control unsatisfactory curative effect of patients immune system and chronic inflammation, thus its
There is certain limitation in curative effect.
Summary of the invention
In view of the defects and deficiencies of the prior art, the present invention intends to provide a kind of for treating the compound of diabetes
Snake lotus mixture.
To achieve the above object, the technical solution adopted by the present invention is that: it includes following parts by weight of component: 9 parts of kuh-seng, white
12-25 parts of taste lotus, 30 parts of potentilla discolor, 30-120 parts of Radix Astragali, 20-60 parts of pueraria lobata, 20-50 parts of Chinese yam, 20 parts of Morinda officinalis, Radix Salviae Miltiorrhizae
30-50 parts, 15 parts of hairyvein agrimony, 10 parts of barberry, l0 parts of fried atractylodes, l0 parts of Yun Ling, l0 parts of radix scrophulariae, l0 parts of stir-baked FRUCTUS CRATAEGI.
White taste lotus, barberry, kuh-seng clearing heat and promoting diuresis, dissipate stasis of blood resolving sputum, dispel cause the phlegm pyreticosis of diabetes because；
Radix Salviae Miltiorrhizae promoting blood circulation cool blood, relieving restlessness and restlessness, the clinical symptoms of reduction of patient；
Chinese yam, pueraria lobata replenish qi to invigorate the spleen, and promote the production of body fluid to quench thirst, and improve the symptom of patient's polydipsia；
Radix Astragali, Morinda officinalis air making-up and spleen enlivening, yang invigorating, invigorating qi for consolidating superficies, inducing diuresis to remove edema play strengthening the spleen and replenishing qi, ascending the clear and descending the turbid altogether
The benefits of.
After adopting the above scheme, the invention has the following beneficial effects: it is of the present invention a kind of for treating the compound of diabetes
Snake lotus mixture can effectively control blood glucose level in patients, mitigate the diabetic symptoms such as patient mostly drink, frequent micturition, have to diabetes B
There is apparent therapeutic effect.
Specific embodiment
The present invention is further illustrated below.
Embodiment 1: it include following parts by weight of component: 9 parts of kuh-seng, 12 parts of white taste lotus, 30 parts of potentilla discolor, 30 parts of Radix Astragali,
20 parts of pueraria lobata, 20 parts of Chinese yam, 20 parts of Morinda officinalis, 30 parts of Radix Salviae Miltiorrhizae, 15 parts of hairyvein agrimony, 10 parts of barberry, l0 parts of fried atractylodes, Yun Ling
L0 parts, l0 parts of radix scrophulariae, l0 parts of stir-baked FRUCTUS CRATAEGI；
Embodiment 2: it includes following parts by weight of component: 9 parts of kuh-seng, 25 parts of white taste lotus, 30 parts of potentilla discolor, Radix Astragali 120
Part, 60 parts of pueraria lobata, 50 parts of Chinese yam, 20 parts of Morinda officinalis, 50 parts of Radix Salviae Miltiorrhizae, 15 parts of hairyvein agrimony, 10 parts of barberry, l0 parts of fried atractylodes, cloud
L0 parts of Siberian cocklebur, l0 parts of radix scrophulariae, l0 parts of stir-baked FRUCTUS CRATAEGI；
Embodiment 3: it include following parts by weight of component: 9 parts of kuh-seng, 20 parts of white taste lotus, 30 parts of potentilla discolor, 85 parts of Radix Astragali,
40 parts of pueraria lobata, 35 parts of Chinese yam, 20 parts of Morinda officinalis, 40 parts of Radix Salviae Miltiorrhizae, 15 parts of hairyvein agrimony, 10 parts of barberry, l0 parts of fried atractylodes, Yun Ling
L0 parts, l0 parts of radix scrophulariae, l0 parts of stir-baked FRUCTUS CRATAEGI；
Embodiment 4: it includes following parts by weight of component: 9 parts of kuh-seng, 15 parts of white taste lotus, 30 parts of potentilla discolor, Radix Astragali 110
Part, 45 parts of pueraria lobata, 35 parts of Chinese yam, 20 parts of Morinda officinalis, 35 parts of Radix Salviae Miltiorrhizae, 15 parts of hairyvein agrimony, 10 parts of barberry, l0 parts of fried atractylodes, cloud
L0 parts of Siberian cocklebur, l0 parts of radix scrophulariae, l0 parts of stir-baked FRUCTUS CRATAEGI.
Compound prescription snake lotus mixture for treating diabetes of the invention shows that the present invention can have by following pharmacological testings
Effect control blood glucose level in patients mitigates the diabetic symptoms such as patient mostly drink, frequent micturition, there is apparent treatment to make diabetes B
With；
Pharmacological testing: randomly selecting 210 diabetics, and according to being admitted to hospital, number is randomly divided into control group and observation group,
Control group and each 105 of observation group；Wherein control group patient male 52, women 53,55.8 ± 10.8 one full year of life of age, the course of disease
2.0 ± 1.2 years；Observation group patient male 57, women 48,58.6 ± 10.4 one full year of life of age, the course of disease 2.2 ± 1.3 years；System
Meter is learned analysis shows statistical difference is not present in two groups of patients in the distribution of age, gender and the course of disease, is as a result had comparable
Property；
The diagnosis of diabetes B is carried out using the standard of ADA in 1997；The insulin resistance of patient uses insulin releasing
Test is detected；Be included in standard: patient meets the diagnostic criteria of diabetes B, and with insulin resistance and pancreas islet
The horizontal relative deficiency of element；Patient occurs including the clinical symptoms such as dry, more drinks, frequent micturition and body syntexis；Patient's voluntary participation
This experimental study, and sign informed consent form；
Exclusion criteria: not meeting diabetes B diagnostic criteria, or is type 1 diabetes patient: merge cardiovascular and cerebrovascular, liver,
The main organs serious change such as kidney；Gestation and breast feeding women；There is the patient of severe diabetes mellitus complication；Severe infections,
Tumour, autoimmune disease and other general diseases patient；Other situations such as informed consent form are not signed；
Control group patient receive conventional western medicine treatment, drug include insulin secretion accelerating class drug, insulin sensitizer with
And alpha-glucosidase inhibitor, it is treated according to original doctor formula；Observation group patient receive compound prescription snake lotus mixture of the present invention into
Row treatment；It is added and subtracted according to the clinical symptoms of patient and Chinese medical discrimination type with disease in therapeutic process；Two groups of patients were in treatment 8 weeks
After compare curative effect.
Two groups of patients 1 day measurement fasting blood glucose level, postprandial two hours blood after treatment starts first 1 day and treatment end
The indexs such as sugar level, saccharification hemoglobin content；Therapeutic evaluation is carried out according to following standard: it is significant effectively: it is patient's dry, more
The symptoms such as drink, frequent micturition disappear or are obviously improved, blood glucose level obviously lowers and restores normal；It is effective: Patients Patients' dry, more
The symptoms such as drink, frequent micturition are improved, blood glucose level obviously lowers but do not restore normal level；Invalid: blood glucose level in patients does not obtain
To reduction, or even increase, while clinical symptoms are not improved.
All data are collected and are arranged using Microsoft Excel software, and are counted using SPSS18.0
Credit analysis；Enumeration data analyzes the conspicuousness of difference using chi-square criterion, and measurement data uses the form of average value ± standard deviation
It indicates, and uses the conspicuousness of student t check analysis difference；P < 0.05 thinks that difference has conspicuousness, and has statistics
Learn meaning；
Test result is as follows:
1, the comparison of two groups of pretherapy and post-treatment blood glucose levels of patient
The blood glucose level of pretherapy and post-treatment two groups of patients is more as shown in table 1；The result shows that control group and observation group patient exist
Receive fasting blood-glucose and postprandial two hours blood glucose levels after treating to be substantially reduced, and pretherapy and post-treatment blood glucose level is with aobvious
It writes sex differernce (p < 0.001).Illustrate that Western medicine and Chinese medicine treatment all have obvious effect for controlling the blood glucose level of patient.Together
When, paired observation group and control group patient treatment after blood glucose level, it has been found that: observation group's patient's fasting blood-glucose is bright after treatment
It is aobvious to be lower than control group patient, and difference has statistical significance (t=10.434, p < 0.001)；Observation group patient is postprandial after treatment
Two hours blood glucose is significantly lower than control group patient, and difference has statistical significance (t=8.74, p < 0.001)；Prompt Chinese medicine is controlled
It treats for controlling the effect of patient blood glucose due to western medicine.
The comparison (mmol) of 1 two groups of pretherapy and post-treatment blood glucose levels of patient of table
2, the comparison of two groups of pretherapy and post-treatment glycated hemoglobin levels of patient:
Two groups of pretherapy and post-treatment glycated hemoglobin levels of patient are as shown in table 2；The result shows that after drug therapy, two groups of patients
Glycated hemoglobin levels obviously lower.In addition, receiving observation group's patient's glycosylated hemoglobin of compound prescription snake lotus mixture treatment
Level is lower than control group patient (t=3.815, p=0.0002), and difference has statistical significance.
The comparison (mg/dl) of 2 two groups of pretherapy and post-treatment glycated hemoglobin levels of patient of table
| Grouping | Case load (n) | Before treatment | After treatment | T value | P value |
| Control group | 105 | 7.85±1.81 | 6.92±1.54 | 4.023 | <0.001 |
| Observation group | 105 | 7.56±1.89 | 6.26±0.84 | 6.458 | <0.001 |
3, the comparison of two groups of pretherapy and post-treatment glycated hemoglobin levels of patient:
The comparison of two groups of patient's curative effects is as shown in table 3；The result shows that the curative effect of control group and observation group patient have obviously
Difference (χ 2=11.832, p=0.0027), and the curative effect of observation group patient is substantially better than control group.
The curative effect of 3 control group of table and observation group compares
| Grouping | Case load | It is significant effective | Effectively | In vain |
| Control group | 105 | 35 | 43 | 17 |
| Observation group | 105 | 62 | 36 | 7 |
Test result shows: compound prescription snake lotus mixture of the present invention has apparent therapeutic effect for type 2 diabetic patient, can
To be effectively reduced the blood glucose level of patient, saccharification hemoglobin content is reduced, to blood glucose and saccharification hemoglobin content
Reduction effect is slightly better than western medicine；In addition, compound prescription snake lotus mixture have in terms of controlling patient symptom compared with Western medicine it is apparent excellent
Gesture, especially in terms of the symptoms such as the more drinks of control and frequent micturition, the action of compound prescription snake lotus mixture is very fast, can control trouble in a short time
The symptom of person, effect are obvious.
The above is merely illustrative of the technical solution of the present invention, rather than limits those of ordinary skill in the art to this hair
The other modifications or equivalent replacement that bright technical solution is made, as long as it does not depart from the spirit and scope of the technical scheme of the present invention,
It is intended to be within the scope of the claims of the invention.
Claims (5)
1. a kind of for treating the compound prescription snake lotus mixture of diabetes, it is characterised in that it includes following parts by weight of component: kuh-seng 9
Part, 12-25 parts of white taste lotus, 30 parts of potentilla discolor, 30-120 parts of Radix Astragali, 20-60 parts of pueraria lobata, 20-50 parts of Chinese yam, 20 parts of Morinda officinalis,
30-50 parts of Radix Salviae Miltiorrhizae, 15 parts of hairyvein agrimony, 10 parts of barberry, l0 parts of fried atractylodes, l0 parts of Yun Ling, l0 parts of radix scrophulariae, l0 parts of stir-baked FRUCTUS CRATAEGI.
2. according to claim 1 a kind of for treating the compound prescription snake lotus mixture of diabetes, it is characterised in that it includes such as
Lower parts by weight of component: 9 parts of kuh-seng, 12 parts of white taste lotus, 30 parts of potentilla discolor, 30 parts of Radix Astragali, 20 parts of pueraria lobata, 20 parts of Chinese yam, Morinda officinalis
20 parts, 30 parts of Radix Salviae Miltiorrhizae, 15 parts of hairyvein agrimony, 10 parts of barberry, l0 parts of fried atractylodes, l0 parts of Yun Ling, l0 parts of radix scrophulariae, l0 parts of stir-baked FRUCTUS CRATAEGI.
3. according to claim 1 a kind of for treating the compound prescription snake lotus mixture of diabetes, it is characterised in that it includes such as
Lower parts by weight of component: 9 parts of kuh-seng, 25 parts of white taste lotus, 30 parts of potentilla discolor, 120 parts of Radix Astragali, 60 parts of pueraria lobata, 50 parts of Chinese yam, Morinda officinalis
20 parts, 50 parts of Radix Salviae Miltiorrhizae, 15 parts of hairyvein agrimony, 10 parts of barberry, l0 parts of fried atractylodes, l0 parts of Yun Ling, l0 parts of radix scrophulariae, l0 parts of stir-baked FRUCTUS CRATAEGI.
4. according to claim 1 a kind of for treating the compound prescription snake lotus mixture of diabetes, it is characterised in that it includes such as
Lower parts by weight of component: 9 parts of kuh-seng, 20 parts of white taste lotus, 30 parts of potentilla discolor, 85 parts of Radix Astragali, 40 parts of pueraria lobata, 35 parts of Chinese yam, Morinda officinalis
20 parts, 40 parts of Radix Salviae Miltiorrhizae, 15 parts of hairyvein agrimony, 10 parts of barberry, l0 parts of fried atractylodes, l0 parts of Yun Ling, l0 parts of radix scrophulariae, l0 parts of stir-baked FRUCTUS CRATAEGI.
5. according to claim 1 a kind of for treating the compound prescription snake lotus mixture of diabetes, it is characterised in that it includes such as
Lower parts by weight of component: 9 parts of kuh-seng, 15 parts of white taste lotus, 30 parts of potentilla discolor, 110 parts of Radix Astragali, 45 parts of pueraria lobata, 35 parts of Chinese yam, Morinda officinalis
20 parts, 35 parts of Radix Salviae Miltiorrhizae, 15 parts of hairyvein agrimony, 10 parts of barberry, l0 parts of fried atractylodes, l0 parts of Yun Ling, l0 parts of radix scrophulariae, l0 parts of stir-baked FRUCTUS CRATAEGI.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910130305.7A CN109806328A (en) | 2019-02-21 | 2019-02-21 | It is a kind of for treating the compound prescription snake lotus mixture of diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910130305.7A CN109806328A (en) | 2019-02-21 | 2019-02-21 | It is a kind of for treating the compound prescription snake lotus mixture of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109806328A true CN109806328A (en) | 2019-05-28 |
Family
ID=66607127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910130305.7A Pending CN109806328A (en) | 2019-02-21 | 2019-02-21 | It is a kind of for treating the compound prescription snake lotus mixture of diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109806328A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103768331A (en) * | 2012-10-23 | 2014-05-07 | 刘思波 | Medicine for treating diabetes |
-
2019
- 2019-02-21 CN CN201910130305.7A patent/CN109806328A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103768331A (en) * | 2012-10-23 | 2014-05-07 | 刘思波 | Medicine for treating diabetes |
Non-Patent Citations (3)
| Title |
|---|
| 严兆义: "辨证分型治疗2型糖尿病150例", 《安徽中医学院学报》 * |
| 杨仁虎: ""复方蛇莲合剂治疗糖尿病的临床疗效观察"", 《中西医结合心血管病电子杂志》 * |
| 牛红英: "中西医结合治疗2型糖尿病合并高血脂的临床疗效分析", 《现代诊断与治疗》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111658701A (en) | Spleen-tonifying traditional Chinese medicine composition and application thereof | |
| CN109806328A (en) | It is a kind of for treating the compound prescription snake lotus mixture of diabetes | |
| CN100586465C (en) | Chinese medicine composition for treating melancholia and preparation method thereof | |
| CN102861201A (en) | Medicine composition for treating diabetes and preparation method thereof | |
| CN100388950C (en) | Application of human urokinase-type peptidase in preparing medicine for treating diabetes combined cerebral infraction | |
| Wu et al. | Analysis of pharmacoeconomic value of sitagliptin in the treatment of diabetes mellitus. | |
| CN105456734A (en) | Traditional Chinese medicine for treating diabetes | |
| Cha et al. | A case of combined Korean-Western medicine treatment on Chorea Hyperglycemia Basal Ganglia syndrome induced by nonketotic diabetes mellitus | |
| CN104069384A (en) | Traditional Chinese medicine powder for treating type II diabetes mellitus qi deficiency and blood stasis | |
| Sun et al. | Linggui Zhugan Decoction: A Potential Weight Reduction Solution via Gut Microbiota and Cinnamic Acid Metabolites | |
| Shi et al. | [Retracted] Insulin Aspart Combined with Exercise Therapy in Spleen Deficiency Type Gestational Diabetes Mellitus: The Effect on Disease Control and Pregnancy Outcomes | |
| CN101396518A (en) | Traditional Chinese medicine composition for treating diabetes and complication | |
| CN1330343C (en) | Life prolonging tumour inhibiting cancer treating Chinese medicine oral liquid and its preparation method | |
| CN111437362B (en) | Traditional Chinese medicine composition for adjuvant treatment of middle and late intestinal cancer and preparation method and application thereof | |
| CN110433204B (en) | Chinese medicine compound preparation and its preparing method and use | |
| Gao et al. | Clinical effect of individualized nursing care in diabetic nephropathy patients undergoing hemodialysis | |
| CN102772540B (en) | A kind of medicine for the treatment of metabolism syndrome | |
| CN105875769A (en) | Peanut-skin biscuits and making method thereof | |
| CN104352714A (en) | Traditional Chinese medicine composition for treating spleen deficiency dampness-overabundance type sugar tolerance reduction | |
| Kuang et al. | EFFECTS OF HIGH-DOSE VS. ROUTINE-DOSE CONTINUOUS HEMODIAFILTRATION ON TREATMENT OUTCOMES IN PLAYERS WITH SEVERE PANCREATITIS | |
| CN103961392B (en) | Traditional Tibetan medicine for treating diabetes | |
| CN116115710A (en) | Traditional Chinese medicine composition for protecting liver and stomach, tonifying deficiency and reducing blood glucose | |
| CN105395829A (en) | Efficient blood sugar lowering drug | |
| CN1850151A (en) | Chinese medicinal liquid of acupuncture point cupping for preventing and treating infant's respiration diseases, and preparing method | |
| CN1768778A (en) | Application of cassia seed in preparation of lead-remove promoting drug or health-caring product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190528 |